Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 10/20 | 0.73 |
| ▸ | ADRB2 | P07550 | 9/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18016254 | 1.00 | CHRM3 (0.73) | CHRM3ADRB2KDM4EALDH1A1LMNA | |
| SCHEMBL18016249 | 1.00 | CHRM3 (0.73) | CHRM3ADRB2KDM4EALDH1A1LMNA | |
| SCHEMBL18016248 | 0.95 | CHRM3 (0.71) | CHRM3ADRB2KDM4EALDH1A1LMNA | |
| SCHEMBL20307235 | 0.95 | CHRM3 (0.71) | CHRM3ADRB2KDM4EALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL17978876 | 0.95 | CHRM3 (0.70) | CHRM3ADRB2KDM4EALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL17978877 | 0.95 | CHRM3 (0.70) | CHRM3ADRB2KDM4EALDH1A1LMNA | |
| SCHEMBL24404524 | 0.89 | CHRM3 (0.73) | CHRM3ADRB2KDM4EALDH1A1LMNA | |
| SCHEMBL18017291 | 0.89 | CHRM3 (0.73) | CHRM3ADRB2KDM4EALDH1A1LMNA | |
| SCHEMBL18016247 | 0.89 | CHRM3 (0.76) | CHRM3ADRB2BCHEACHEMAOB | |
| SCHEMBL20307241 | 0.89 | CHRM3 (0.76) | CHRM3ADRB2KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10004728-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10004728-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2B | CHRM3 12/4885ADRB2 1/4885KDM4E 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.